Does the media refer more to ROIV or IMVT?

In the previous week, Immunovant had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 17 mentions for Immunovant and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.67 beat Immunovant's score of 0.42 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IMVT or BNTX more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% BioNTech -63.54% -6.86% -6.00%

Does the media prefer IMVT or BNTX?

In the previous week, BioNTech had 11 more articles in the media than Immunovant. MarketBeat recorded 28 mentions for BioNTech and 17 mentions for Immunovant. BioNTech's average media sentiment score of 0.44 beat Immunovant's score of 0.42 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 10 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or INSM more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Insmed -76.94% -123.94% -44.30%

Does the media prefer IMVT or INSM?

In the previous week, Immunovant had 10 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Immunovant and 7 mentions for Insmed. Immunovant's average media sentiment score of 0.42 beat Insmed's score of 0.17 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Insmed 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, IMVT or INCY?

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Incyte $5.14B 4.39 $1.29B $7.85 14.19

Is IMVT or INCY more profitable?

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Incyte 27.71% 29.93% 22.88%

Does the media favor IMVT or INCY?

In the previous week, Immunovant had 8 more articles in the media than Incyte. MarketBeat recorded 17 mentions for Immunovant and 9 mentions for Incyte. Immunovant's average media sentiment score of 0.42 beat Incyte's score of 0.24 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Incyte 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to UTHR or IMVT?

In the previous week, Immunovant had 3 more articles in the media than United Therapeutics. MarketBeat recorded 17 mentions for Immunovant and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Immunovant's score of 0.42 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Immunovant (IMVT) Competitors

$28.71 -0.77 (-2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$28.54 -0.18 (-0.61%)

As of 07:30 PM Eastern

Compare

IMVT vs. ROIV, BNTX, INSM, INCY, and UTHR

Should you buy Immunovant stock or one of its competitors? Immunovant's main competitors and comparable companies include Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), Incyte (INCY), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunovant compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Immunovant had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 17 mentions for Immunovant and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.67 beat Immunovant's score of 0.42 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,317.20	-$299.77M	-$0.53	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Immunovant	N/A	-69.59%	-62.49%

Roivant Sciences currently has a consensus target price of $45.64, suggesting a potential upside of 31.94%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 49.25%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Roivant Sciences beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

Immunovant (NASDAQ:IMVT) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

In the previous week, BioNTech had 11 more articles in the media than Immunovant. MarketBeat recorded 28 mentions for BioNTech and 17 mentions for Immunovant. BioNTech's average media sentiment score of 0.44 beat Immunovant's score of 0.42 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	10 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
BioNTech	-63.54%	-6.86%	-6.00%

Immunovant presently has a consensus target price of $44.00, indicating a potential upside of 49.25%. BioNTech has a consensus target price of $125.69, indicating a potential upside of 31.14%. Given Immunovant's higher possible upside, equities research analysts plainly believe Immunovant is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunovant has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
BioNTech	$3.25B	7.47	-$1.29B	-$7.83	N/A

Immunovant has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

BioNTech beats Immunovant on 10 of the 16 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Immunovant (NASDAQ:IMVT) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Immunovant has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Immunovant has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Insmed	$1.14B	18.92	-$1.28B	-$4.11	N/A

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Insmed	-76.94%	-123.94%	-44.30%

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 49.25%. Insmed has a consensus price target of $200.30, indicating a potential upside of 103.23%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Insmed	1 Sell rating(s)	1 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Immunovant had 10 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Immunovant and 7 mentions for Insmed. Immunovant's average media sentiment score of 0.42 beat Insmed's score of 0.17 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Insmed	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Immunovant beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Immunovant compare to Incyte?

Immunovant (NASDAQ:IMVT) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Immunovant presently has a consensus price target of $44.00, suggesting a potential upside of 49.25%. Incyte has a consensus price target of $127.70, suggesting a potential upside of 14.67%. Given Immunovant's stronger consensus rating and higher possible upside, analysts clearly believe Immunovant is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, Immunovant had 8 more articles in the media than Incyte. MarketBeat recorded 17 mentions for Immunovant and 9 mentions for Incyte. Immunovant's average media sentiment score of 0.42 beat Incyte's score of 0.24 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Incyte	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Incyte has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Incyte	$5.14B	4.39	$1.29B	$7.85	14.19

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Incyte	27.71%	29.93%	22.88%

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Incyte beats Immunovant on 11 of the 16 factors compared between the two stocks.

How does Immunovant compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

United Therapeutics presently has a consensus target price of $627.31, suggesting a potential upside of 14.04%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 49.25%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Immunovant had 3 more articles in the media than United Therapeutics. MarketBeat recorded 17 mentions for Immunovant and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Immunovant's score of 0.42 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

United Therapeutics has a net margin of 41.56% compared to Immunovant's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Immunovant	N/A	-69.59%	-62.49%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 1.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Summary

United Therapeutics beats Immunovant on 12 of the 15 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.09B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	9.71	193.11	18.97
Price / Sales	N/A	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	6.85	16.95	10.71	6.03
Net Income	-$505.61M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-10.59%	-4.83%	-3.18%	-3.04%
1 Month Performance	-23.15%	-12.20%	-6.61%	-5.16%
1 Year Performance	65.48%	8.87%	3.69%	-2.48%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	2.4477 of 5 stars	$28.71 -2.6%	$44.00 +53.3%	+73.1%	$6.09B	N/A	N/A	315
ROIV Roivant Sciences	2.7333 of 5 stars	$35.78 +0.2%	$45.64 +27.5%	+115.6%	$25.80B	$8.26M	N/A	721	Analyst Downgrade
BNTX BioNTech	3.908 of 5 stars	$97.64 +0.8%	$126.00 +29.0%	-6.1%	$24.50B	$3.25B	N/A	7,807	Gap Down
INSM Insmed	2.7531 of 5 stars	$103.83 -6.6%	$200.57 +93.2%	-39.3%	$24.27B	$606.42M	N/A	1,664	Trending News Analyst Forecast Options Volume Analyst Revision Gap Down High Trading Volume
INCY Incyte	4.0644 of 5 stars	$114.13 -1.0%	$127.45 +11.7%	+32.9%	$23.37B	$5.82B	14.54	2,844	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. ROIV, BNTX, INSM, INCY, and UTHR

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to BioNTech?

Summary

How does Immunovant compare to Insmed?

Summary

How does Immunovant compare to Incyte?

Summary

How does Immunovant compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. ROIV, BNTX, INSM, INCY, and UTHR

How does Immunovant compare to Roivant Sciences?

Does the media refer more to ROIV or IMVT?

Which has more volatility and risk, ROIV or IMVT?

Which has better earnings & valuation, ROIV or IMVT?

Is ROIV or IMVT more profitable?

Do analysts recommend ROIV or IMVT?

Do institutionals & insiders have more ownership in ROIV or IMVT?

Summary

How does Immunovant compare to BioNTech?

Does the media prefer IMVT or BNTX?

Is IMVT or BNTX more profitable?

Do analysts rate IMVT or BNTX?

Do institutionals and insiders believe in IMVT or BNTX?

Which has preferable earnings and valuation, IMVT or BNTX?

Which has more volatility and risk, IMVT or BNTX?

Summary

How does Immunovant compare to Insmed?

Which has more risk & volatility, IMVT or INSM?

Which has stronger valuation and earnings, IMVT or INSM?

Is IMVT or INSM more profitable?

Do analysts rate IMVT or INSM?

Does the media prefer IMVT or INSM?

Do institutionals & insiders believe in IMVT or INSM?

Summary

How does Immunovant compare to Incyte?

Do analysts recommend IMVT or INCY?

Does the media favor IMVT or INCY?

Which has more volatility and risk, IMVT or INCY?

Which has preferable earnings and valuation, IMVT or INCY?

Is IMVT or INCY more profitable?

Do insiders and institutionals have more ownership in IMVT or INCY?

Summary

How does Immunovant compare to United Therapeutics?

Do analysts prefer UTHR or IMVT?

Does the media refer more to UTHR or IMVT?

Is UTHR or IMVT more profitable?

Do institutionals and insiders believe in UTHR or IMVT?

Which has higher valuation and earnings, UTHR or IMVT?

Which has more volatility & risk, UTHR or IMVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools